Filter results by

Guidance and Policy (5343)
Guidance (1607)
Quality Indicators (1)
Prescribing and Technical Information (5310)
Primary Research (5)
Practice Based Information (42)
Audit and Inspection Reports (42)
Medicines Current Awareness (30)
Implementation Support (1)

Area of interest

Drugs and Technologies (30)

Source

Action on Smoking and Health - ASH (1)
Age UK (2)
All Wales Medicines Strategy Group - AWMSG (6)
Alzheimer's Society (1)
British Heart Foundation (1)
British Society for Haematology (1)
Care Quality Commission - CQC (6)
Department of Health (2)
Diabetes UK (2)
electronic Medicines Compendium - eMC (251)
European Medicines Agency - EMA (98)
European Society of Cardiology - ESC (1)
GOV UK (2)
Health Foundation (10)
Healthcare Quality Improvement Partnership - HQIP (3)
House of Commons (1)
King's Fund (10)
Local Government Association (2)
Medicines and Healthcare products Regulatory Agency - MHRA (85)
National Audit Office - NAO (3)
National Institute for Health and Care Excellence - NICE (323)
NHS England (73)
NHS Improvement (12)
NHS Providers (1)
NHS RightCare (2)
NIHR Dissemination Centre (20)
Nuffield Trust (7)
Public Health England - PHE (61)
Royal College of Obstetricians and Gynaecologists - RCOG (2)
Royal College of Paediatrics and Child Health - RCPCH (1)
Royal Pharmaceutical Society (9)
Specialist Pharmacy Service (55)
US Food and Drug Administration - FDA (28)

British National Formulary for Children - BNFc (0)
Royal College of Psychiatrists - RCPsych (1)
Brain Tumour Charity (0)
Arthritis Research UK (0)
Canadian Paediatric Society (0)
British HIV Association - BHIVA (0)
European Society of Gastrointestinal Endoscopy (0)
Cochrane Database of Systematic Reviews (0)
Scottish Medicines Consortium - SMC (29)

Date

From

To

View filters

Share
Linked In
Twitter
Facebook
Email
More...

Results for all evidence | Drugs and Technologies | Scottish Medicines Consortium - SMC | Medicines Current Awareness 1 - 10 of 30 sorted by relevance / date

Click export CSV or RIS to download the entire page or use the checkboxes to select a subset of records to download

Warning, download options selected.

The operation that you have selected will move away from the current results page, your download options will not persist.

Please click "Confirm" if you are happy to lose these search results.

mexiletine (Namuscla) not recommended for use within NHSScotland

Remove: Scottish Medicines Consortium - SMC source - 09 March 2020 - Publisher: Scottish Medicines Consortium

The SMC has rejected mexiletine for symptomatic treatment of myotonia in adults with non-dystrophic myotonic disorders. The Committee concluded that the submitting company’s justification of...

More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter
blinatumomab (Blincyto) accepted for restricted use within NHSScotland

Remove: Scottish Medicines Consortium - SMC source - 09 March 2020 - Publisher: Scottish Medicines Consortium

The SMC has accepted blinatumomab for the treatment of adults with Philadelphia chromosome negative, CD19 positive, B-precursor acute lymphoblastic leukaemia (ALL) in first or second complete...

SPS comment

- More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter
lorlatinib (Lorviqua) accepted for use within NHSScotland on an interim basis subject to ongoing evaluation and reassessment

Remove: Scottish Medicines Consortium - SMC source - 09 March 2020 - Publisher: Scottish Medicines Consortium

The SMC has accepted lorlatinib monotherapy for treatment of anaplastic lymphoma kinase (ALK)-positive advanced NSCLC whose disease has progressed after alectinib or ceritinib as the first ALK...

SPS comment

- More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter
sodium zirconium cyclosilicate (Lokelma®) not recommended for use within NHSScotland

Remove: Scottish Medicines Consortium - SMC source - 10 February 2020 - Publisher: Scottish Medicines Consortium

The SMC does not recommend sodium zirconium cyclosilicate for treatment of hyperkalaemia in adult patients. The submitting company did not present a sufficiently robust economic analysis to gain...

SPS comment

- More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter
encorafenib (Braftovi®) accepted for use within NHSScotland

Remove: Scottish Medicines Consortium - SMC source - 10 February 2020 - Publisher: Scottish Medicines Consortium

The SMC has accepted encorafenib in combination with binimetinib for the treatment of adults with unresectable or metastatic melanoma with a BRAF V600 mutation.

SPS comment

- More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter
teduglutide (Revestive®) accepted for use within NHSScotland

Remove: Scottish Medicines Consortium - SMC source - 10 February 2020 - Publisher: Scottish Medicines Consortium

The SMC has accepted teduglutide for the treatment of patients age 1 year and above with short bowel syndrome (SBS). Patients should be stable following a period of intestinal adaptation after...

More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter
plerixafor (Mozobil®) accepted for use within NHSScotland

Remove: Scottish Medicines Consortium - SMC source - 10 February 2020 - Publisher: Scottish Medicines Consortium

The SMC has accepted plerixafor in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in...

SPS comment

- More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter
cemiplimab (Libtayo®) accepted for use within NHSScotland on an interim basis subject to ongoing evaluation and future reassessment

Remove: Scottish Medicines Consortium - SMC source - 10 February 2020 - Publisher: Scottish Medicines Consortium

The SMC has accepted cemiplimab as monotherapy for the treatment of adults with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or...

SPS comment

- More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter
SMC initial assessment of evidence for burosumab for X-linked hypophosphataemia with radiographic evidence of bone disease in children 1 year of age and older and adolescents

Remove: Scottish Medicines Consortium - SMC source - 10 February 2020 - Publisher: Scottish Medicines Consortium

The SMC has advised that the Scottish Government Medicines Policy Branch will notify Health Boards when this medicine is available for prescribing within the ultra-orphan pathway. In the meantime, ...

More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter
SMC initial assessment of evidence for voretigene neparvovec (Luxturna) for treatment of vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations

Remove: Scottish Medicines Consortium - SMC source - 10 February 2020 - Publisher: Scottish Medicines Consortium

The SMC has advised that the Scottish Government Medicines Policy Branch will notify Health Boards when this medicine is available for prescribing within the ultra-orphan pathway. In the meantime, ...

More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter

1
2
3
Next